Sign Up to like & get
recommendations!
1
Published in 2017 at "Cytopathology"
DOI: 10.1111/cyt.12493
Abstract: Liquid‐based (LB)‐FNA is widely recognized as a reliable diagnostic method to evaluate thyroid nodules. However, up to 30% of LB‐FNA remain indeterminate according to the Bethesda system. Use of molecular biomarkers has been recommended to…
read more here.
Keywords:
molecular testing;
accuracy;
testing braf;
braf ras ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-5160
Abstract: REDX05358 has been identified as a novel, highly selective and potent next generation pan RAF inhibitor with improved therapeutic potential and predicted safety profile. Aberrant signalling via the MAPK pathway is commonly seen in cancer.…
read more here.
Keywords:
braf;
ras mutant;
braf ras;
raf inhibitor ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Endocrine-related cancer"
DOI: 10.1530/erc-16-0402
Abstract: A unique prognostic role of the genetic duet of BRAF V600E and TERT promoter mutations in papillary thyroid cancer (PTC) has been recently established, but the role of RAS mutation in this genetic interplay remains…
read more here.
Keywords:
braf v600e;
braf;
braf ras;
cancer ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms18040806
Abstract: Molecular markers are helpful diagnostic tools, particularly for cytologically indeterminate thyroid nodules. Preoperative RET/PTC1 rearrangement analysis in BRAF and RAS wild-type indeterminate thyroid nodules would permit the formulation of an unambiguous surgical plan. Cycle threshold…
read more here.
Keywords:
ptc1 rearrangement;
ras wild;
ret ptc1;
braf ras ... See more keywords